Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4701-4708

  Millar, Ewan K A ^a   Graham, Peter H ^a   O'Toole, Sandra A ^a   McNeil, Catriona M ^a   Browne, Lois ^a   Morey, Adrienne L ^a   Eggleton, Sarah ^a   Beretov, Julia ^a   Theocharous, Constantine ^a   Capp, Anne ^a   Nasser, Elias ^a   Kearsley, John H ^a   Delaney, Geoff ^a   Papadatos, George ^a   Fox, Christopher ^a   Sutherland, Robert L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CONSERVING THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BREAST TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70350441646     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.7075     Document Type: Article

References (33)

1. Wapnir IL, Anderson SJ, Mamounas EP, et al: Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical
2. Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24:2028-2037, 2006
3. Clarke M, Collins R, Darby S, et al: Early Breast Cancer Trialists' Collaborative Group: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005
4. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406: 747-752, 2000
5. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
6. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA 295:2492-2502, 2006
7. Neilsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast cancer. Clin Cancer Res 10:5367-5374, 2004
8. Cheang MC, Voduc D, Bajdik C, et al: Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008
9. Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol 26:2373-2378, 2008
10. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: A critical review. J Clin Oncol 26: 2568-2581, 2008
11. Millar EKA, Anderson LR, McNeil CM, et al: BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. Br J Cancer 100:123-133, 2009
12. st planned analysis at 6 year median follow-up. Australasian Radiology 51:A85, 2007 (suppl 3)
13. Haffty BG, Fischer D, Beinfield M, et al: Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21:293-298, 1991
14. Whelan T, Clark R, Roberts R, et al: Ipsilateral breast tumor recurrence post lumpectomy is predictive of subsequent mortality: Results from a randomized trial. Int J Radiat Oncol Biol Phys 30:11-16, 1994
15. Haffty BG, Reiss M, Beinfield M, et al: Ipsilateral breast tumor recurrence as a predictor of distant disease: Implications for systemic therapy at the time of local relapse. J Clin Oncol 14:52-57, 1996
16. Calle R, Vilcoq JR, Zafrani B, et al: Local control and survival of breast cancer treated by limited surgery followed by irradiation. Int J Radiat Oncol Biol Phys 12:873-878, 1986
17. Arriagada R, Le MG, Contesso G, et al: Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol 13:1404-1413, 2002
18. Early Breast Cancer Trialists' Collaborative Group: Favourable and unfavourable effects on longterm survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 355: 1757-1770, 2000
19. Fowble BL, Schultz DJ, Overmoyer B, et al: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 30:23-33, 1994
20. Sanghani M, Balk E, Cady B, et al: Predicting the risk of local recurrence in patients with breast cancer: An approach to a new computer-based predictive tool. Am J Clin Oncol 30:473-480, 2007
21. Graham P, Fourquet A: Placing the boost in breast-conservation radiotherapy: A review of the role, indications and techniques for breast boost radiotherapy. Clin Oncol 18:210-219, 2006
22. Haffty BG, Yang Q, Reiss M, et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657, 2006
23. Dent R, Trudeau M, Pritchard KI, et al: Triple negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007
24. Kyndi M, Sorensen FB, Knudsen H, et al: Estrogen receptor, progesterone receptor, HER-2, and response to post mastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419-1426, 2008
25. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004
26. Mamounas EP, Tang G, Bryant J, et al: Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Presented at the 28th Annual San Antonio Breast Cancer Symposium Meeting, December 8-11, 2005, San Antonio, TX
27. Musgrove EA, Sergio MS, Loi S, et al: Identi-fication of functional networks of estrogen and c-Myc responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE 3:e2987, 2008
28. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
29. Nuyten DSA, Kreike B, Hart AAM, et al: Predicting local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 8:R62, 2006
30. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
31. Romestaing H, Lehingue Y, Carrie C, et al: Role of a 10 Gy boost in the conservative treatment of early breast cancer: Results of a randomised clinical trial in Lyon, France. J Clin Oncol 15:963-968, 1997
32. Bartelink H, Horiot JC, Poortmans PM, et al: Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25:3259-3265, 2007
33. Polgar C, Fodor J, Orosz Z, et al: Electron and high dose rate brachytherapy boost in the conservative treatment of stage I-II breast cancer: First results of the randomised Budapest boost trial. Strahlenther Onkol 178:615-623, 2002